Beijing Beilu Pharmaceutical

Beilu Pharmaceutical released its 2026 interim report on August 25, 2026. The company's total operating revenue was 673 million yuan, net profit attributable to the parent company was 79.7521 million yuan, and net cash inflow from operating activities was 134 million yuan. The company's latest asset-liability ratio was 26.22%, gross margin was 43.85%, down 2.67 percentage points from the previous quarter and down 3.22 percentage points from the same period last year, and latest return on equity was 3.20%. The company's diluted earnings per share was 0.14 yuan, total asset turnover was 0.19 times, and inventory turnover was 0.94 times. The company had 39,000 shareholders, and the top ten shareholders held 162 million shares, accounting for 27.90% of total share capital.